文献速递心外重症与机械循环支持

原位心脏移植后新发恶性肿瘤的特征:单中心20年结局

Characterization of de novo malignancy after orthotopic heart transplantation: single-centre outcomes over 20 years.
PubMed 文献 · Eur J Cardiothorac Surg · 2023-01-01

该单中心回顾性研究纳入1999至2018年488例原位心脏移植患者,评估术后新发皮肤和实体器官恶性肿瘤的竞争风险。移植后1、5、10年皮肤恶性肿瘤累积发生率分别为2%、17%、27%,实体器官恶性肿瘤为1%、5%、12%。年龄、政府支付保险、恶性肿瘤家族史和二甲双胍使用与皮肤癌风险增加相关,年龄和恶性肿瘤家族史与实体器官癌风险增加相关。

要点

  • 移植后1、5、10年皮肤恶性肿瘤累积发生率为2%、17%、27%,实体器官恶性肿瘤为1%、5%、12%。
  • 年龄、政府支付保险、恶性肿瘤家族史和二甲双胍使用与皮肤癌风险增加相关。
  • 年龄和恶性肿瘤家族史与实体器官癌风险增加相关,最常见为前列腺癌和肺癌。

核心结论

  • 原位心脏移植受者晚期随访中需警惕恶性肿瘤并监测免疫抑制,皮肤和实体器官恶性肿瘤累积发生率随时间推移而增加,移植后恶性肿瘤的关键危险因素需识别并常规监测。

研究设计与样本

  • 单中心回顾性研究,纳入1999至2018年在该机构接受原位心脏移植的患者488例。
  • 以死亡和皮肤和/或实体器官恶性肿瘤发生作为竞争风险进行评估。
  • 采用Fine-Gray亚分布风险回归评估围术期患者和供者特征与远期恶性肿瘤结局的关联。

主要发现

  • 移植后1、5、10年,估计分别有2%、17%、27%的患者发生皮肤恶性肿瘤,分别有1%、5%、12%的患者发生实体器官恶性肿瘤。
  • 多变量Fine-Gray回归显示,年龄[1.05(1.03-1.08);P < 0.001]、政府支付保险[1.77(1.20-2.59);P = 0.006]、恶性肿瘤家族史[1.66(1.15-2.38);P = 0.007]和二甲双胍使用[1.73(1.15-2.59);P = 0.008]与黑色素瘤和基底或鳞状细胞癌风险增加相关。
  • 年龄[1.08(1.04-1.12);P < 0.001]和恶性肿瘤家族史[2.55(1.43-4.56);P = 0.002]与实体器官癌风险增加相关,最常见为前列腺癌和肺癌。

临床怎么用

  • 作者认为,原位心脏移植受者晚期随访中需警惕恶性肿瘤并监测免疫抑制,移植后恶性肿瘤的关键危险因素需识别并常规监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Malignancy is the leading cause of late mortality after orthotopic heart transplantation (OHT), and the burden of post-transplantation cancer is expected to rise in proportion to increased case volume following the 2018 heart allocation score change. In this report, we evaluated factors associated with de novo malignancy after OHT with a focus on skin and solid organ cancers. METHODS: Patients who underwent OHT at our institution between 1999 and 2018 were retrospectively reviewed (n = 488). Terminal outcomes of death and development of skin and/or solid organ malignancy were assessed as competing risks. Fine-Gray subdistribution hazards regression was used to evaluate the association between perioperative patient and donor characteristics and late-term malignancy outcomes. RESULTS: By 1, 5 and 10 years, an estimated 2%, 17% and 27% of patients developed skin malignancy, while 1%, 5% and 12% of patients developed solid organ malignancy. On multivariable Fine-Gray regression, age [1.05 (1.03-1.08); P < 0.001], government payer insurance [1.77 (1.20-2.59); P = 0.006], family history of malignancy [1.66 (1.15-2.38); P = 0.007] and metformin use [1.73 (1.15-2.59); P = 0.008] were associated with increased risk of melanoma and basal or squamous cell carcinoma. Age [1.08 (1.04-1.12); P < 0.001] and family history of malignancy [2.55 (1.43-4.56); P = 0.002] were associated with an increased risk of solid organ cancer, most commonly prostate and lung cancer. CONCLUSIONS: Vigilant cancer and immunosuppression surveillance is warranted in OHT recipients at late-term follow-up. The cumulative incidence of skin and solid organ malignancies increases temporally after transplantation, and key risk factors for the development of post-OHT malignancy warrant identification and routine monitoring.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Bakir NH, Florea IB, Phillipps J, et al. Characterization of de novo malignancy after orthotopic heart transplantation: single-centre outcomes over 20 years. Eur J Cardiothorac Surg. 2023. PMID: 37815836. doi:10.1093/ejcts/ezad341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。